Research groups

GE05 Genitourinary diseases

Our research group is denominated GE05 Genitourinary diseases, and encompasses a multidisciplinary team of both basic and clinical post-doctoral researchers who are specialized in the area, pre-doctoral researchers, and staff in charge of coordination of clinical trials. All of them are committed to quality translational research.

Our main activities include the study of the tumoral pathology of the genitourinary system and associated oncological research. We develop various lines of research in this area, aimed at the discovery of new biomarkers for the diagnosis and prognosis of urological tumors (Bladder Cancer, Prostate Cancer and Kidney).

Currently, our group carries out several research projects focused on the identification of non-muscle invasive bladder cancer prognostic factors. The results could contribute to the development of a genetic signature test to be used for the prognosis of bladder cancer. A more accurate prognosis is important as it is decisive for the selection of the most optimal and individualized treatment for each patient, thus improving patient care and health outcomes.

We also maintain stable collaboration with the biotechnology company Life length in the context of the European project called ONCOCHECK (that was granted to the company within the Horizon 2020 Framework Program) and more recently PROSTAV (focused on validating the results). ONCOCHECK and PROSTAV aim at deepening the knowledge of genetic factors, such as the measurement of Chromosomal length, which can influence the development of prostate cancer and its clinical evolution. Our group is one of the partners participating in the project’s clinical study in prostate cancer.

In the field of kidney transplantation, our group is focused on the search for new strategies that improve the prognosis of the transplanted organ. Finally, the group's experience in the field of robotic surgery could play an important role in the field of laparoscopic surgery.

Research Lines

We have a long history in the study of the mechanisms involved in the progressive acquisition of specific genetic changes at the cellular level and molecular level in bladder cancer. We study the level of genetic and protein expression of different genes involved in the regulation mechanisms of the cell cycle, cell proliferation, angiogenesis and invasion by metastasis, as well as the genes involved in cell regulation related to cancer progression. Obtaining new specific molecular biomarkers can be useful in the development of diagnostic and prognostic models of bladder carcinoma.

We carry out an observational epidemiological study in collaboration with the Spanish Prostate Cancer Group (GESCAP), on the progression of PCa and the therapeutic approach of patients with this pathology. This study aims to establish an effective non-invasive method for the diagnosis, prognosis and therapeutic stratification of PCa that increases the specificity of PSA and thus avoid unnecessary prostate biopsies. The study involves also an analysis of the current care patterns of PCa in Andalusia and their results in health care.

Our group has led the configuration of the BROCA robot, which is considered the first Spanish Project of Surgical Robot, and represents a major advance in the innovation of laparoscopic surgery techniques. The development of this initiative has already concluded with a prototype derived from three patents, which will lay the foundations of a business project. Setting up a start-up company for the final development and future commercialization of the product is planned.

Networks

    Life Length – a biotechnology-based company whose activity focuses on the commercialization of the TAT telomere measurement technique

    CTS-172 Urological Pathology (Andalusian Plan for Research, Development and Innovation PAIDI)

     

Keywords

  • bladder cancer
  • prostate cancer
  • kidney transplantation
  • biomarkers
  • diagnosis
  • prognosis
  • predictive
  • robotic laparoscopic surgery

Additional Information

Awards and Grants

Grant Leonardo de la Peña 2016 for the project: Identification of a panel of molecular biomarkers with prognostic significance in patients with high-grade pT1 bladder cancer. PI: María José Requena Tapia

Grant Leonardo de la Peña 2014 for the project: Study of the expression levels of the proteins of the signaling pathway Pl3CA / AKT and its diagnostic and prognostic / predictive role in urinary bladder cancer. PI: María José Requena Tapia

Research grant Pedro Cifuentes Díaz, within the call for Foundation for the investigation of the year 2012 for the project: Prevalence of renal lithiasis in the population of 40 to 64 years of Andalusia: PreLiRenA Study. Authors: MJose Requena, Fco Jose Anglada, Luis Perula, Miguel Arrabal, Julia Carrasco, Roque Cano

Research grant in Urology Pedro Cifuentes Díaz within the call for Foundation for Research of the year 2010 for the project: Antioxidant therapy in the application of lithotripsy in patients with renal lithiasis. Authors: Anglada Curado FJ, Requena Tapia MJ, Carrasco Valiente J, Padillo Ruiz FJ.

Patents

Authors: Raúl M. Luque Huertas, Justo P. Castaño Fuentes, Manuel D. Gahete Ortíz, Alejandro Ibañez Costa, Daniel Hormaechea Gulla, Juan Manuel Jimenez Vacas,  André Moráis Sarmento Borges Cabral, Fernando López López, María José Requena Tapia, Enrique Gómez Gómez, Julia Carrasco Valiente.
Title: Non-invasive diagnostic method of cancer.
Owner: Andalusian Public Health System and University of Cordoba    
(In collaboration between GC-08 and GE05)

Authors: María José Requena, Enrique Gómez Gómez, Julia Carrasco Valiente, Jesús Ruiz García, M.D. Luque De Castro, F. Priego Capote, M. Calderón Santiago, María Auxiliadora Fernández Peralbo.
Title: Biomarkers for screening and diagnosis of prostate cancer.
Owner: Andalusian Public Health System and University of Cordoba    
(In Collaboration between GE-05 GC-08  and GC-21)

Authors: Rafael Medina Carnicer, Rafael Muñoz Salinas, María José Requena Tapia, José Eduardo Arjona Berral, Rosa María Paredes Esteban, A. Salvatierra Velázquez, Ignacio Muñoz Carvajal,Javier Briceño Delgado, Enrique Bauzano Núñez, Mª Carmen López Casado, Victor Fernando Muñoz Martínez,  Julius Klein Hubert, Asier Fernández Iribar.
Title: TOOL COUPLING 
Owner: Fundación Tecnalia Research & Innovation, University of Cordoba, Andalusian Public health System, University of Malaga          
(In collaboration between GC19 GC18 GE05 GA01 and GA09)

Collaborations

ONCOCHECK Project: European Project, funded by the Horizon 2020 Framework Program

Biotechnology company Life Length

GE05 Genitourinary diseases

Principal Investigator
María José Requena Tapia

Post-Doctoral Researchers
Ana María Blanca Pedregosa
Juan Pablo Campos Hernández
Julia Carrasco Valiente

Clinical Researchers
Francisco Anglada Jurado
Javier Márquez López
Rafael Prieto Castro
Jesús Ruiz García
José Valero Rosa

Pre-Doctoral Researchers
Juan Manuel Rubio Galisteo
Álvaro Sánchez González

Projects

Active projects

Regional

Carrasco Valiente, J. Prostate cancer management patterns in Andalusia and evaluation of health outcomes in prostate cancer. Funding agency: Regional Ministry of Equality, Health and Social Policy (CISPS). Reference: PI-0126-2016.

National

Antonio López Beltrán; María José Requena Tapia; Ana María Blanca Pedregosa; Juan Pablo Campos Hernández; Jesús Ruiz García; Álvaro Sánchez González. Desarrollo de un perfil de expresión génica con valor pronóstico y predictivo en carcinoma vesical. Funding agency: Instituto de Salud Carlos III. Reference: PI17/01981

Requena Tapia, MJ. Improved patient wellbeing and safety in management procedures using collaborative systems. m-LISTABLE. Funding agency: Spanish Ministry of Economy and Competitiveness (MINECO). Reference: RTC-2016-5149_003       

Requena Tapia, MJ. Identificación de un panel de biomarcadores moleculares con significación pronóstica en pacientes con cáncer de vejiga pT1 de alto grado. Funding agency: Asociacion Española de Urologia. Reference: FIU16/001

International

Requena Tapia, MJ. ONCOCHECK - A simple blood test for prognosis and monitoring of patients undergoing cancer therapy. Funding agency: European Commission. Reference: SMEInst-2017-01 (Subcontractor)

Publications

Publications 2019

Gomez-Gomez E, Jimenez-Vacas JM, Pedraza-Arevalo S, Lopez-Lopez F, Herrero-Aguayo V, Hormaechea-Agulla D, Valero-Rosa J, Ibanez-Costa A, Leon-Gonzalez AJ, Sanchez-Sanchez R, Gonzalez-Serrano T, Requena-Tapia MJ, Castano JP, Carrasco-Valiente J, Gahete MD, Luque RM. Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. JOURNAL OF CLINICAL MEDICINE. 2019 Sep 6;8(9):1400. doi: 10.3390/jcm8091400.
IF: 5,688
D: 1

Jimenez-Vacas JM, Herrero-Aguayo V, Gomez-Gomez E, Leon-Gonzalez AJ, Saez-Martinez P, Alors-Perez E, Fuentes-Fayos AC, Martinez-Lopez A, Sanchez-Sanchez R, Gonzalez-Serrano T, Lopez-Ruiz DJ, Requena-Tapia MJ, Castano JP, Gahete MD Luque RM. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. TRANSLATIONAL RESEARCH. 2019 Oct;212:89-103. doi: 10.1016/j.trsl.2019.07.001.
IF: 4,915
D: 1

Frantzi M, Gomez EG, Pedregosa AB, Rosa JV, Latosinska A, Culig Z, Merseburger AS, Luque RM, Tapia MJR, Mischak H, Valiente JC; CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. BRITISH JOURNAL OF CANCER. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z.
IF: 5,416
Q: 1

Gomez-Gomez E, Carrasco-Valiente J, Campos-Hernandez JP, Blanca-Pedregosa AM, Jimenez-Vacas JM, Ruiz-Garcia J, Valero-Rosa J, Luque RM, Requena-Tapia MJ; Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994.
IF: 4,658
Q: 1

Volavsek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, Cimadamore A, Vau N, Pierconti F, Lopez-Beltran A; Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. VIRCHOWS ARCHIV. 2019 Dec;475(6):735-744. doi: 10.1007/s00428-019-02666-x.
IF: 2,868
Q: 2

Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L, Cimadamore A, Montironi R, Lopez-Beltran A; Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. APMIS. 2019 Aug;127(8):545-553. doi: 10.1111/apm.12973.
IF: 2,225
Q: 2

Gomez Gomez E, Salamanca Bustos JJ, Carrasco Valiente J, Fernandez Rueda JL, Blanca A, Valero Rosa J, Bravo Arrebola I, Marquez López J, Jimenez Vacas JM, Luque R, Requena Tapia MJ. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA. BMJ Open. 2019 Nov 12;9(11):e031032. doi: 10.1136/bmjopen-2019-031032.
IF: 2,376
Q: 2

Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer. J Clin Med. 2019 Nov 22;8(12):2056. doi: 10.3390/jcm8122056.
IF: 5,688
D: 1

Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019 Dec;11(17):1507-1521. doi: 10.2217/imt-2019-0115.
IF: 3,028
Q: 3

Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, Cimadamore A, Lopez-Beltran A. Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index nodule. Hum Pathol. 2019 Nov;93:6-15. doi: 10.1016/j.humpath.2019.08.012.
IF: 2,74
Q: 2

Main Publications 2018

Gómez Gómez, E., Valero Rosa, J., Carrasco Valiente, J., Triviño Tarradas, F., Anglada Curado, F., López Ruiz, D., Requena Tapia, M.J. New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience (2018) Urology, 121, pp. 198-199.
IF:2.3,
Q: 2

Carrasco, J., Gómez, E., García, J.H., Valero, J., Sánchez, Á., Salamanca, J.J., Campos, J.P., Requena, M.J. Impact of the use of simulators on the mental workload and confidence in a digital rectal examination and bladder catheterization workshop [Article@Impacto del uso de simuladores sobre la carga mental y la confianza en un taller de tacto rectal y cateterizaciÓn vesical en estudiantes] (2018) Archivos Espanoles de Urologia, 71 (6), pp. 537-542.

Carrasco Valiente, J., Ruiz García, J.M., Requena Tapia, M.J. Oligometastatic prostate cancer. Concept and implications [Article@Cáncer de próstata oligometastásico. Concepto e implicaciones] (2018) Archivos Espanoles de Urologia, 71 (3), pp. 239-246.

Sánchez-Hidalgo, J.M., Salamanca-Bustos, J.J., Arjona-Sánchez, Á., Campos-Hernández, J.P., Ruiz Rabelo, J., Rodríguez-Benot, A., Requena-Tapia, M.J., Briceño-Delgado, J. What Is the Influence of Both Risk Donor and Risk Receiver on Simultaneous Pancreas-Kidney Transplantation? (2018) Transplantation Proceedings, 50 (2), pp. 664-668.
IF: 0.806
Q: 4

Salamanca-Bustos, J.J., Gomez-Gomez, E., Campos-Hernández, J.P., Carrasco-Valiente, J., Ruiz-García, J., Márquez-López, F.J., Zurera-Tendero, L., Requena-Tapia, M.J. Initial Experience in the Use of Novel Auto-expandable Metal Ureteral Stent in the Treatment of Ureter Stenosis in Kidney Transplanted Patients (2018) Transplantation Proceedings, 50 (2), pp. 587-590.
IF: 0.806
Q: 4

Other Publications 2018

Gómez-Gómez, E., Jiménez-Vacas, J.M., Carrasco-Valiente, J., Herrero-Aguayo, V., Blanca-Pedregosa, A.M., León-González, A.J., Valero-Rosa, J., Fernández-Rueda, J.L., González-Serrano, T., López-Miranda, J., Gahete, M.D., Castaño, J.P., Requena-Tapia, M.J., Luque, R.M. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. (2018) Journal of Cellular and Molecular Medicine, 22 (11), pp. 5688-5697. Cited 1 time. DOI: 10.1111/jcmm.13845
IF: 4.302
Q: 1

Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. FRONTIERS IN ONCOLOGY. 2018; 8: Núm artículo 456
IF: 4,416 
Q: 2

Volavsek M, Blanca A, Montironi R, Cheng L, Raspollini MR, Vau N, Fonseca J, Pierconti F, Lopez-Beltran A. Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. VIRCHOWS ARCHIV. 2018; 472(3):451-460.
IF: 2,936  
Q: 2

Zamorano-Leon JJ, Segura A, Lahera V, Rodriguez-Pardo JM, Prieto R, Puigvert A, Farre AJL. Relationship Between Erectile Dysfunction, Diabetes and Dyslipidemia in Hypertensive-Treated Men. UROLOGY JOURNAL. 2018; 15(6):370-375.
IF: 0,88 
Q: 4

Arjona-Sanchez A, Rodriguez-Ortiz L, Sanchez-Hidalgo JM, Rabelo JR, Salamanca-Bustos JJ, Rodriguez-Benot A, Campos-Hernandez P, Briceno-Delgado J. Intraoperative Heparinization During Simultaneous Pancreas-Kidney Transplantation: Is It Really Necessary?. TRANSPLANTATION PROCEEDINGS. 2018; 50(2):673-675.
IF: 0,806 
Q: 4

Sanchez-Hidalgo JM, Rodriguez-Ortiz L, Arjona-Sanchez A, Ruiz-Rabelo J, Salamanca-Bustos JJ, Rodriguez-Benot A, Marquez-Lopez FJ, Briceno-Delgado J. Pancreas Donor Hypernatremia: Is it Really a Risk Factor for Simultaneous Pancreas-kidney Transplantation?. TRANSPLANTATION PROCEEDINGS. 2018; 50(2):676-678.
IF: 0,806  
Q: 4

Puigvert AM, Prieto R, Garcia F. Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities. REVISTA INTERNACIONAL DE ANDROLOGIA. 2018; 16(1):28-33.
IF: 0,096  
Q: 4

Main Publications 2017

Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. CURRENT DRUG METABOLISM. 2017.18(8):712-722.
IF: 2,659
Q: 2 

Gomez-Gomez E, Carrasco-Valiente J, Blanca-Pedregosa A, Barco-Sanchez B, Fernandez-Rueda JL, Molina-Abril H, Valero-Rosa J, Font-Ugalde P, Requena-Tapia MJ. European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. UROLOGY. 2017.102():85-91.
IF: 2,309
Q: 2 

Pedregosa AMB, Sanchez-Gonzalez A, Valiente JC, Garcia JMR, Gomez EG, Beltran AL, Tapia MJR. Expression of proteins FGFR3, PI3 K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance. ACTAS UROLOGICAS ESPANOLAS. 2017.41(3):172-180.
IF: 1,181
Q: 4 

Valiente JC, Gomez EG, Tapia MJR. Epidemiology of urinary lithiasis in Spain: New scenarios. ARCHIVOS ESPANOLES DE UROLOGIA. 2017.70(1):3-11.
IF: 0,323
Q: 4 

Prieto R, Cruz N, Cabello F, Garcia F, Fernandez A, Larrazabal M, Martin A, Sanchez F, Martin CS, Viladoms J. Diagnosis, treatment and follow-up of premature ejaculation: Expert's recommendations. REVISTA INTERNACIONAL DE ANDROLOGIA. 2017.15(2):70-77.
IF: 0,261
Q: 4 

Carrasco J, Arias MR, Perula LA, Campos JP, Prieto R, Requena MJ. Renal lithiasis, erectile dysfunction and ADAM test: Observational study using telephone survey. REVISTA INTERNACIONAL DE ANDROLOGIA. 2017.15(4):153-159.
IF: 0,261
Q: 4 

Other Publications

Pedraza-Arevalo S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, Selth LA, Gahete MD, Castano JP, Luque RM. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. PROSTATE. 2017.77(15):1499-1511.
IF: 3,82
Q: 1 

Hormaechea-Agulla D, Gahete MD, Jimenez-Vacas JM, Gomez-Gomez E, Ibanez-Costa A, L-Lopez F, Rivero-Cortes E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sanchez-Sanchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castano JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. MOLECULAR CANCER. 2017.16():-146.
IF: 6,204
Q: 1 

Hormaechea-Agulla D, Jimenez-Vacas JM, Gomez-Gomez E, Lopez FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sanchez-Sanchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibanez-Costa A, Gahete MD, Requena MJ, Castano JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB JOURNAL. 2017.31(11):4682-4696.
IF: 5,498
Q: 1  D: 1

Izquierdo L, Montalbo R, Ingelmo-Torres M, Mallofre C, Ramirez-Backhaus M, Rubio J, Van der Heijden AG, Schaafsma E, Lopez-Beltran A, Blanca A, Lawrentschuk N, Alcaraz A, Mengual L. Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. ONCOTARGET. 2017.8(31):51522-51529.
IF: 5,168
Q: 1 

Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A. Tp53 and its potential therapeutic role as a target in bladder cancer. EXPERT OPINION ON THERAPEUTIC TARGETS. 2017.21(4):401-414.
IF: 4,873
Q: 1 

Lopez-Beltran A, Paner G, Blanca A, Montironi R, Tsuzuki T, Nagashima Y, Chuang SS, Win KT, Madruga L, Raspollini MR, Cheng L. In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. VIRCHOWS ARCHIV. 2017.471(4):561-562.
IF: 2,848
Q: 2 

Lopez-Beltran A, Paner G, Blanca A, Montironi R, Tsuzuki T, Nagashima Y, Chuang SS, Win KT, Madruga L, Raspollini MR, Cheng L. Lymphoepithelioma-like carcinoma of the upper urinary tract. VIRCHOWS ARCHIV. 2017.470(6):703-709.
IF: 2,848
Q: 2  

Cruz-Navarro N, Prieto-Castro R, Cabello-Santamaria F, Garcia-Jose F, Fernandez-Lozano A, Larrazabal-Murillo M, Martin-Morales A, Sanchez-Sanchez F, San Martin-Blanco C, Viladoms-Fuster J, Grp Elaborador Recomendaciones. From the definition to the social impact of premature ejaculation. Expert consensus. ACTAS UROLOGICAS ESPANOLAS. 2017.41(5):281-283.
IF: 1,181
Q: 4 

Vega RA, de Torres LAP, Garcia CJ, Valiente JC, Tapia MJR, Castineira RC, Aycaguer LCS. Comorbidity and socio-demographic factors associated with renal lithiasis in persons aged 40 to 65: A cross-sectional study. MEDICINA CLINICA. 2017.149(9):383-390.
IF: 1,125
Q: 3 

Clinical Research

Active in 2018

A randomized, double-bind, comparative study of ZYTIGA (abiraterone acetate) plus prednisone at low dose plus androgen deprivation therapy (ADT) against TPA alone in subjects with a new diagnosis of high-risk metastatic hormone-naive  prostate cancer (mHNPC).
PI: Dr. María José Requena Tapia

Phase III, randomized, placebo-controlled, double-blind JNJ-56021927 in combination with abiraterone acetate and prednisone compared with abiraterone acetate and prednisone in patients with metastatic-resistant prostate cancer.
PI: Dr. María José Requena Tapia

A phase 3 randomized, placebo-controlled, double-blind study of apalutamide plus androgen deprivation therapy (ADT) in subjects with metastatic hormone-sensitive prostate cancer (mHSPC). Estudio TITAN.
PI: Dr. María José Requena Tapia

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-center, double-blind, placebo-controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 targeting the SHIP1 Pathway in Subjects with Interstitial Cyst.
PI: Dr. María José Requena Tapia

Estudio observacional y transversal para la optimización del diagnóstico de metástasis en fase de CPRC M0 en la práctica clínica habitual en España (Estudio IDENTIFICA).
PI: Dr. María José Requena Tapia

Características y manejo de los pacientes diagnosticados de síntomas del tracto urinario inferior por hiperplasia benigna de próstata  atendidos en España.
PI: Dr. María José Requena Tapia

Members

Dra. María José Requena Tapia

Principal Investigator

Team

Ana María Blanca Pedregosa, Juan Pablo Campos Hernández, Julia Carrasco Valiente, Francisco Anglada Jurado, Javier Márquez López, Rafael Prieto Castro, Jesús Ruiz García, José Valero Rosa, Juan Manuel Rubio Galisteo, Álvaro Sánchez González